Medical research has confirmed that lung cancer occurs due to the accumulation of mutations in dozens of genes (including oncogenes and oncogenes, etc.) in the body, coupled with the stimulation of environmental carcinogenic factors. Certain genes in human body are closely related to the effects of targeted or chemotherapeutic drugs for lung cancer treatment. To test these specific genes, simply speaking, tumor tissue cells or cancerous pleural fluid of the tested lung cancer patients are extracted and purified, and then genetic information is extracted and purified. The genetic information can be extracted and purified by specific equipment to analyze the genetic status to predict the sensitivity of patients to various anti-tumor drugs, so as to judge the efficacy of drug treatment, and thus improve the targeting and efficiency of anti-cancer drug treatment, and minimize or avoid the accompanying treatment and over-treatment which are widely concerned by the society. Currently, the efficiency of chemotherapy for lung cancer is still low, and in the past, chemotherapy drugs were selected according to clinical experience, from which many lung cancer patients did not gain clinical benefit. Nowadays, lung cancer-related genetic tests, such as EGFR, K-RAS, ALK, ERCC1 and RRM1, are performed on tumor biopsies or surgically resected tumor tissues and pathological specimens, and the results of the genetic tests are used to select which chemotherapeutic drug or molecularly targeted therapeutic drug to individualize lung cancer treatment. The reason why targeted therapy is called targeted is that these molecular targeted drugs are developed and designed to kill only tumor cells in a targeted manner to avoid accidentally injuring normal tissue cells in human body, and to provide highly selective treatment or precise treatment according to specific molecular targets. Therefore, it is especially important to test for the corresponding gene status before choosing targeted drug therapy. Clinical studies have confirmed that patients with EGFR-sensitive mutations in non-small cell lung cancer who take EGFR-TKI targeted drugs such as Erysart, Troche or Kemena are more than ten times more effective than those without EGFR mutations. The targeted selection of molecular targeted drugs through lung cancer-related gene testing allows lung cancer patients with gene mutations to receive accurate and timely individualized treatment, while non-small cell lung cancer patients without EGFR gene mutations can avoid accompanying treatment or over-treatment. With the continuous development and clinical application of molecular targeted therapies, the treatment mode of more advanced non-small cell lung cancer patients has been converted to that of chronic lifestyle diseases, such as hypertension, diabetes and coronary heart disease, where lung cancer can be effectively controlled by taking drugs at home every day, making it possible for lung cancer patients to receive treatment with dignity and live with quality cancer, which we have been advocating and expecting. This makes it possible for lung cancer patients to receive treatment with dignity and live a quality life with cancer.